Clinical Trial Update: Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study evaluating Hum-195/rGel, an anti-CD-33 immunotoxin, in patients with advanced myeloid malignancies including acute myeloid leukemia and chronic my…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Anemia with Excess Blasts
• Myelomonocytic Leukemia
• Myeloproliferative Neoplasms

Drugs mentioned

• Hum-195/rGel (Hum-195/rGel immunotoxin)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 1 | Status: COMPLETED